These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10563597)

  • 41. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany.
    Strzelczyk A; Haag A; Reese JP; Nickolay T; Oertel WH; Dodel R; Knake S; Rosenow F; Hamer HM
    Epilepsy Behav; 2013 Jun; 27(3):433-8. PubMed ID: 23591262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Economic aspects of drug-resistant epilepsy].
    Owczarek K; Jedrzejczak J
    Neurol Neurochir Pol; 2001; 35(2):309-18. PubMed ID: 11599228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic evaluation of epilepsy treatment: a review of the literature.
    Heaney DC; Begley CE
    Epilepsia; 2002; 43 Suppl 4():10-6. PubMed ID: 12059996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accurate diagnosis and long term management is problem in epilepsy, not cost of drugs.
    Coebergh J
    BMJ; 2013 Jun; 346():f3920. PubMed ID: 23778279
    [No Abstract]   [Full Text] [Related]  

  • 45. [Social and economic aspects of administration of new antiepileptic drugs].
    Dławichowska E; Owczarek K; Fiszer U
    Neurol Neurochir Pol; 2001; 35(2):245-52. PubMed ID: 11599223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The economic effects of introducing vigabatrin, a new antiepileptic medication.
    Reinharz D; Kennedy W; Contandriopoulos AP; Tessier G; Champagne F
    Pharmacoeconomics; 1995 Nov; 8(5):400-9. PubMed ID: 10160074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS).
    Beghi E; Garattini L; Ricci E; Cornago D; Parazzini F;
    Epilepsia; 2004 Feb; 45(2):171-8. PubMed ID: 14738425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How to use the new epilepsy drugs.
    Hall W
    Practitioner; 1995 Feb; 239(1547):125-8. PubMed ID: 7708616
    [No Abstract]   [Full Text] [Related]  

  • 49. New drugs: which should be included in the formulary? Epilepsy: all new drugs should be included.
    Pierre-Louis SJ
    Arch Neurol; 2000 Feb; 57(2):272-3. PubMed ID: 10681089
    [No Abstract]   [Full Text] [Related]  

  • 50. Profile of antiepileptic pharmacotherapy in a tertiary referral center in South India: a pharmacoepidemiologic and pharmacoeconomic study.
    Radhakrishnan K; Nayak SD; Kumar SP; Sarma PS
    Epilepsia; 1999 Feb; 40(2):179-85. PubMed ID: 9952264
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
    Davis KL; Candrilli SD; Edin HM
    Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The costs of childhood epilepsy in Italy: comparative findings from three health care settings.
    Guerrini R; Battini R; Ferrari AR; Veggiotti P; Besana D; Gobbi G; Pezzani M; Berta E; Tetto A; Beghi E; Monticelli ML; Tediosi F; Garattini L; Russo S; Rasmini P; Amadi A; Quarti P; Fabrizzi R;
    Epilepsia; 2001 May; 42(5):641-6. PubMed ID: 11380572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic impact of epilepsy and the cost of nonadherence to antiepileptic drugs in older Medicare beneficiaries.
    Ip Q; Malone DC; Chong J; Harris RB; Labiner DM
    Epilepsy Behav; 2018 Mar; 80():208-214. PubMed ID: 29414554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Problem of managing patients with epilepsy in developing countries.
    Kuruvilla A
    Epilepsia; 1999 Oct; 40(10):1465-6. PubMed ID: 10528947
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost-effectiveness of first-line antiepileptic drug treatments in the developing world: a population-level analysis.
    Chisholm D;
    Epilepsia; 2005 May; 46(5):751-9. PubMed ID: 15857443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comprehensive care of the epilepsy patient--control, comorbidity, and cost.
    Bazil CW
    Epilepsia; 2004; 45 Suppl 6():3-12. PubMed ID: 15315510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients.
    Knoester PD; Deckers CL; Termeer EH; Boendermaker AJ; Kotsopoulos IA; de Krom MC; Keyser T; Renier WO; Hekster YA; Severens HL
    Value Health; 2007; 10(3):173-82. PubMed ID: 17532810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiepileptic therapies in the Mifi Province in Cameroon.
    Preux PM; Tiemagni F; Fodzo L; Kandem P; Ngouafong P; Ndonko F; Macharia W; Dongmo L; Dumas M
    Epilepsia; 2000 Apr; 41(4):432-9. PubMed ID: 10756409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health care costs decline after successful epilepsy surgery.
    Langfitt JT; Holloway RG; McDermott MP; Messing S; Sarosky K; Berg AT; Spencer SS; Vickrey BG; Sperling MR; Bazil CW; Shinnar S
    Neurology; 2007 Apr; 68(16):1290-8. PubMed ID: 17438219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The burden and pharmacoeconomics of epilepsy in India.
    Kuruvilla A
    Seizure; 1999 Oct; 8(7):436-7. PubMed ID: 10600588
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.